Buy Melanotan 1 Online | The A-Z Guide

There is strong research interest in melanotan 1 and this section will summarize the main benefits of melanotan 1 as evidenced by these trials.

Increased melanin production and tanning

MT1 binds strongly to the melanocortin 1 receptor (MC1R), which is involved in the production of melanin, tyrosinase, and melanocyte [2, 3]. Studies have shown that melanotan 1 has a strong impact on both the rate of melanin production and tanning, effectively speeding up the tanning process and reducing the incidence of sunburnt cells in research subjects [4].

According to the findings of three phase I clinical trials conducted by dermatology clinics at the Arizona Health Sciences Center, test subjects who received MT1 injections tanned significantly more easily on their backs compared with the control group, and experienced a 47 percent reduction in sunburn on their necks after receiving small doses of UV-B light [4].

Psychological benefits in recovering patients

There is strong evidence that melanotan I offers psychological benefits such as improvements in both outlook and mood in patients recovering from various ailments.

• A phase II clinical trial involving patients who had received photodynamic therapy (PDT) found that melanotan 1 improved mood and outlook compared with the control group. The trial, sponsored by Clinuvel Pharmaceuticals, concluded that MT1 could potentially be used as a post-PDT treatment for patients in this population [8].

• Melanotan 1 has also been investigated as a treatment for patients who have undergone photodynamic therapy with porfimer sodium. According to a 2008 phase II multicentre, double-blind, placebo-controlled pilot study, patients who received melanotan 1 implants derived several psychological benefits including improvements in mood [8].

A follow-up trial has sought to evaluate the safety of subcutaneous bioresorbable implants of melanotan I but results from this trial are unavailable [9]. This provides researchers with several potential directions for future research involving MT1.

Potential treatment for acne vulgaris

There is strong research interest in melanotan 1 as a potential treatment of acne vulgaris and at least one phase 2 trial has already investigated the peptide for this purpose.

In a 2011 phase II randomized study, test subjects were administered melanotan 1 injections at either a three-week interval or two injections at one-month intervals. The study, conducted in Germany, found that patients who received subcutaneous bioresorbable melanotan 1 implants experienced an improvement in their quality of life (measured by DLQI) and a reduction in the number of inflammatory acne lesions on their faces. Further, subjects who received melanotan could spend up to seven times longer in the sun compared with the control group [10]. Results for a follow-up trial are currently unavailable [11].

Potential treatment for light sensitivity disorders

Melanotan 1 has been investigated as a potential treatment for a variety of rare light sensitivity disorders, including:

• Xeroderma pigmentosum (XP), a rare condition that causes extreme sensitivity to ultraviolet (UV) light;
• Polymorphic light eruption (PLE), where sunlight causes skin rashes; and,
• Erythropoietic Protoporphyria (EPP).

While research into the use of MT1 to treat these conditions is ongoing, results from phase II studies indicate that melanotan I holds promise.

• For example, a 2019 proof of concept, phase IIa open-label study conducted in Germany aimed to investigate the use of MT1 to treat XP. Researchers found that melanotan had a favorable safety profile [12], which led to a follow-up study that is currently ongoing [13].
• Likewise, a 2010 phase III, randomized, double-blind, placebo-controlled, parallel-group study undertaken in Europe found that MT1 reduced the severity of PLE when administered as a 16 mg implant over a four-month period [14].
• Lastly, a 2011 European study found that EPP patients treated with MT1 experienced a higher quality of life and less pain compared with a control group [15].